Research Library

A triple-agonist GLP-1/GIP/glucagon receptor peptide studied for obesity and metabolic disease — the highest weight-loss efficacy of any investigational agent to date.

A 15-amino acid pentadecapeptide derived from human gastric juice demonstrating broad tissue-protective and regenerative effects across 200+ preclinical publications.

A synthetic analog of the endogenous thymosin beta-4 peptide with angiogenic, anti-inflammatory, and tissue-repair properties across 170+ preclinical publications.

A synthetic 28-amino acid acetylated thymic peptide that modulates innate and adaptive immunity; approved in 30+ countries for hepatitis B/C and as a cancer immunoadjuvant.

A mitochondria-derived peptide encoded in the 12S rRNA, studied for metabolic regulation, exercise mimicry, insulin sensitization, and longevity.

The body's central redox coenzyme — essential for cellular energy metabolism, DNA repair via PARPs, and sirtuin-mediated longevity pathways.

A short-acting 29-amino-acid GHRH analog studied for pulsatile growth-hormone release. This is the standalone no-DAC compound, not a CJC-1295/Ipamorelin blend.

The long-acting drug-affinity-complex form of CJC-1295. It is a distinct standalone compound from both no-DAC CJC-1295 and CJC-1295/Ipamorelin blends.

A synergistic blend of a GHRH analog and a selective GHRP for dual-pathway pulsatile GH stimulation, achieving ~2.7× potency vs either compound alone.

A 44-amino acid GHRH analog that stimulates pituitary GH secretion — FDA-approved as Egrifta for HIV-associated lipodystrophy.

A selective synthetic pentapeptide GHRP that stimulates GH release via the ghrelin receptor without elevating cortisol or prolactin — the cleanest GHRP profile available.

A synthetic 13-amino acid linear melanocortin analog; FDA/EMA-approved as afamelanotide (Scenesse) for erythropoietic protoporphyria.

The body's master antioxidant tripeptide — central to cellular redox balance, Phase II detoxification, immune function, and mitochondrial protection.

A long-acting acylated GLP-1 receptor agonist; FDA-approved as Ozempic/Wegovy. The single most-searched compound in the research-peptide market.

An investigational fixed combination of the long-acting amylin analog cagrilintide and the GLP-1 agonist semaglutide.

A dual GIP and GLP-1 receptor agonist; FDA-approved as Mounjaro/Zepbound. #2 most-searched compound on the site.

A long-acting acylated amylin analog that complements GLP-1 agonism — being co-developed with semaglutide (CagriSema) for superior weight loss.

A once-daily acylated GLP-1 receptor agonist; FDA-approved as Victoza/Saxenda — the predecessor to semaglutide.

A GLP-1 receptor agonist fused to a modified human IgG4 Fc — a large biologic, not a small peptide; FDA-approved as Trulicity.

A modified C-terminal fragment of human growth hormone with lipolytic activity but without IGF-1 axis stimulation.

Recombinant 191-amino-acid human growth hormone, structurally identical to pituitary hGH.

A synthetic hexapeptide ghrelin/GHS-R agonist that stimulates GH release (with notable appetite stimulation).

A synthetic hexapeptide GH secretagogue (ghrelin mimetic); used clinically in Japan as a GH stimulation test agent.

A synthetic hexapeptide GH secretagogue, a more metabolically stable GHRP-6 analog.

The 1–29 fragment of GHRH that retains full GH-releasing activity; previously FDA-approved (Geref).

A long-acting synthetic analog of IGF-1 with a 13-amino acid N-terminal extension and Arg-3 substitution, designed for dramatically reduced IGFBP binding and extended activity.

An IGF-1 analog truncated at the first three N-terminal residues, with markedly reduced IGFBP binding.

The C-terminal Ec peptide of the IGF-1Ec splice variant, expressed in mechanically loaded muscle.

MGF conjugated to polyethylene glycol to extend its otherwise very short systemic half-life.

The FS-344 isoform of follistatin, a glycoprotein that binds and antagonizes myostatin and activin.

A recombinant glycoprotein hormone that stimulates red blood cell production; FDA-approved (epoetin alfa).

An angiotensin IV-derived small molecule that potentiates the HGF/MET system; studied for synaptogenesis.

A porcine brain-derived mixture of low-molecular-weight neuropeptides and free amino acids with neurotrophic-mimetic activity.

A CNTF (ciliary neurotrophic factor)-derived peptidergic compound studied for BDNF induction and neurogenesis.

A synthetic tetrapeptide analog of the pineal gland extract epithalamin, studied for telomerase activation, antioxidant activity, and longevity effects.

A D-retro-inverso peptide that disrupts the FOXO4–p53 interaction to selectively trigger apoptosis in senescent cells.

A 24-amino-acid mitochondrial-derived peptide encoded in the MT-RNR2 gene with cytoprotective signaling activity.

A mitochondria-targeting tetrapeptide that binds cardiolipin on the inner mitochondrial membrane; investigated clinically.

A naturally occurring copper-binding tripeptide that modulates 4,000+ human genes with regenerative, skin-protective, and wound-healing properties.

A cyclic lactam heptapeptide melanocortin agonist studied for tanning, sexual function, and appetite suppression via MC1R/MC3R/MC4R activation.

A synthetic SNAP-25 mimetic octapeptide that inhibits catecholamine release at the neuromuscular junction, studied for expression line reduction.

A palmitoylated pentapeptide (Pal-KTTKS) derived from a procollagen I fragment, studied for topical collagen support.

A cyclic heptapeptide melanocortin agonist — FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women.

A small molecule inhibitor of NNMT (nicotinamide N-methyltransferase) studied for metabolic regulation and adipose tissue browning effects.

A naturally occurring nonapeptide first isolated from rabbit brain in 1977, studied for sleep regulation, stress response modulation, and circadian rhythm support.

A synthetic tripeptide from the C-terminal of α-MSH with MCR-independent anti-inflammatory activity and gut-protective properties.

A small molecule that inhibits dopamine, norepinephrine, and serotonin transporters. Phase 2 trials studied appetite and weight outcomes. It is not FDA-approved.

A vendor-marketed modified Selank derivative. Sellers do not use one consistent chemical identity, and direct indexed evidence for Adalank was not found during this review.

A copper complex of the Ala-His-Lys tripeptide. Ex vivo and in vitro studies reported effects on human hair follicles and dermal papilla cells. Controlled human efficacy is not established.

A tetrapeptide also identified as KEDG. The available evidence is mainly animal or laboratory work from a limited research lineage. Human clinical benefit is not established.

A phenothiazine redox dye. An FDA-approved intravenous product exists for acquired methemoglobinemia. Research-vendor capsules and droppers are not equivalent to that product.

A synthetic heptapeptide tuftsin analog developed by the Russian Academy of Sciences, approved in Russia and Ukraine for anxiety and cognitive enhancement.

A synthetic ACTH analog developed by the Russian Academy of Sciences, approved in Russia for stroke recovery and cognitive impairment treatment.

A regenerative triple-blend combining BPC-157, TB-500, and GHK-Cu for synergistic tissue repair, angiogenesis, and skin regeneration.

GLOW plus KPV — a four-compound regenerative blend adding MCR-independent anti-inflammatory and gut-protective properties.

A dual-blend of BPC-157 and TB-500 combining complementary regenerative mechanisms: VEGFR2 angiogenesis with actin-mediated cell migration.